MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Beigene Ltd Company Profile (NASDAQ:BGNE)

Consensus Ratings for Beigene Ltd (NASDAQ:BGNE) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.67 (33.11% upside)

Analysts' Ratings History for Beigene Ltd (NASDAQ:BGNE)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyBoost Price Target$39.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Robert W. BairdInitiated CoverageOutperform$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Goldman SachsInitiated CoverageBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Beigene Ltd (NASDAQ:BGNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Beigene Ltd (NASDAQ:BGNE)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Beigene Ltd (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Beigene Ltd (NASDAQ:BGNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Beigene Ltd (NASDAQ:BGNE)
DateHeadline
06/29/16 03:51 PMBeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317 - [at noodls] - WALTHAM, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, ...
06/14/16 03:44 PMU.S. regulator says too many drugmakers chasing same cancer strategy - [Reuters - UK Focus] - A new type of cancer drug that takes the brakes off the body's immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S (Other OTC: UBGXF - news) . Dr. Richard Pazdur, head of the Food and Drug Administration's office of oncology products, was referring to therapies designed to disable the PD-1 protein that tumors use to evade the immune system. The FDA has approved such treatments from Merck (Jakarta: 28586808.JK - news) & Co , Bristol-Myers Squibb Co and Roche Holding AG (LSE: 0QOK.L - news) , each of which have list prices of $150,000 per year.
06/05/16 08:08 AMBeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting - [at noodls] - WALTHAM, Mass., June 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ...
05/19/16 05:52 AMBeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting - [at noodls] - WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ...
05/12/16 03:25 PMBEIGENE, LTD. Files SEC form 10-Q, Quarterly Report -
05/11/16 04:07 PMBeiGene Reports First Quarter 2016 Financial Results - [at noodls] - WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ...
05/04/16 04:41 PMBeiGene Appoints Dr. Ji Li as Executive Vice President, Global Head of Business Development - [at noodls] - WALTHAM, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ('BeiGene'), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs ...
04/28/16 07:03 AMChinese Commodities Brokerage Yintech Debuts on Nasdaq - Yintech is only the third Chinese company to list in the U.S. this year. In the first such IPO of 2016, immuno-oncology drug developer BeiGene Ltd. BGNE-4.65 % raised $182 million on Nasdaq in February. This was followed in March by the $110 million Nasdaq ...
04/21/16 08:30 AMOpening Bell, April 21, 2016 -
04/20/16 09:21 AMBeiGene (Nasdaq: BGNE) to Ring The Nasdaq Stock Market Opening Bell - [at noodls] - ADVISORY, April 20, 2016 (GLOBE NEWSWIRE) -- What: BeiGene (Nasdaq:BGNE), a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics will visit ...
04/19/16 08:26 AMBeiGene Ltd. :BGNE-US: Earnings Analysis: 2015 By the Numbers -
04/18/16 06:44 AMThe 11 year-old Dancing Trumps from Fiske Elementary School in Wellesley, Massachusetts were banned from entering the talent show - newratings.com berichtet: WASHINGTON - BeiGene Ltd 's (BGNE) initial data from an ongoing phase I clinical trial of BGB-283 in patients with BRAF or KRAS/NRAS-mutated cancers has demonstrated that treatment with single-agent BGB-283 is well tolerated with ...
04/18/16 06:40 AMBEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
04/17/16 04:26 PMBeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting - [at noodls] - WALTHAM, Mass., April 17, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ('BeiGene'), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs ...
04/11/16 04:10 PMBEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati -
04/11/16 04:00 PMBeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer - [GlobeNewswire] - WALTHAM, Mass., April 11, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today ...
04/05/16 12:04 PMBEIGENE, LTD. Financials -
04/04/16 03:45 PMWith Biotechnology Companies Leading the Way, Six Venture-Backed IPOs Recorded in First Quarter - In the largest IPO of the quarter, Beijing, China-based BeiGene Ltd (BGNE), raised $182.2 million and began trading on the NASDAQ stock exchange on February 2 nd. At the end of the first quarter, the company traded 22 percent above its $24 offering price.
03/31/16 06:23 AMEarnings Reported After The Bell Mar.30 - Analysts expected the company to report net income of $0.04 per share on revenues of $18.22 million for the period. BeiGene, Ltd. ( BGNE) Q4 net loss was $27.25 million or $3.05 per ADS vs. net loss of $3.74 million or $0.45 per ADS a year ago. Revenue was ...
03/30/16 03:24 PMBEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/30/16 03:05 PMBeiGene Reports Fourth Quarter and Full Year 2015 Financial Results - [GlobeNewswire] - WALTHAM, Mass., March 30, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today ...
03/29/16 03:17 PMBEIGENE, LTD. Files SEC form 8-K, Change in Directors or Principal Officers -
03/16/16 04:48 PMBeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting - [GlobeNewswire] - WALTHAM, Mass., March 16, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced ...
03/07/16 07:02 AM8:02 am BeiGene recieves clinical trial application approval from CFDA to conduct clinical trials with BGB-3111 -
03/07/16 07:00 AMBeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 - [GlobeNewswire] - BEIJING, March 07, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced ...
03/01/16 07:00 AMBeiGene to Present at Cowen and Company 36th Annual Health Care Conference - [GlobeNewswire] - BEIJING, March 01, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced ...
02/29/16 02:33 PMMorgan Stanley: Buy BeiGene's Global Upside - Morgan Stanley’s Matthew Harrison initiated coverage of Beigene Ltd (ADR) (NASDAQ: BGNE) with an Overweight rating and a price target of $39, saying that China opportunity offers valuation support at around $25, while I/O combos offer upside in the ...
02/29/16 01:25 PMStreet Talk: CLR, HLT, BGNE, NFX & FET -
02/29/16 05:46 AMCoverage initiated on BeiGene by Robert W. Baird, Goldman and Morgan Stanley -
02/22/16 03:04 PM13D Filing: Baker Bros. Advisors and Beigene, Ltd. (BGNE) -
02/22/16 11:03 AM13D Filing: Billionaire Lei Zhang’s Hillhouse Capital Management Reports Stake in Beigene, Ltd. (BGNE) -
02/12/16 11:32 AMVolatile Market Flatlines Biotech IPOs -
02/12/16 07:04 AMNo Relief in Sight for IPO Market --Morning MoneyBeat -
02/12/16 05:23 AMOnly biotech companies have braved IPO market this year with a little insider help - Shares of Proteostasis were down as much as 30% from their IPO issue price of $8. Beigene Ltd. BGNE, -11.31% , the first IPO of 2016 and a drug company developing immuno-oncology drugs for cancer treatments, said in its prospectus that two existing ...
02/11/16 04:25 PMBEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, -
02/11/16 03:01 PMOnly biotech companies have braved IPO market this year — with insider help -
02/10/16 11:39 AMBill Gates’ Cascade Investment Boosts AutoNation Inc. (AN) Stake, Buffett Keeps Buying Phillips 66 (PSX), Plus Baker Bros.’ Latest Move -
02/09/16 10:04 AMLittle Hope For IPO Recovery In First Quarter -
02/08/16 03:30 PMBeiGene Announces Closing of Its Initial Public Offering - [GlobeNewswire] - BEIJING, Feb. 08, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced the ...
02/07/16 08:10 AMUp to 8 IPOs Could Launch in the Coming Week -
02/03/16 11:40 AMStrong start for first two IPOs of the year could ease some concerns -
02/03/16 10:55 AMBeiGene Explodes Into the Market -
02/03/16 09:51 AMBeiGene, first IPO of 2016, begins trading above issue price -
About Beigene Ltd

Beigene Ltd logoBeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BGNE
  • CUSIP:
Key Metrics:
  • Previous Close: $29.80
  • 50 Day Moving Average: $29.31
  • 200 Day Moving Average: $28.94
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $674.02M
  • Current Quarter EPS Consensus Estimate: $-3.17 EPS
Additional Links:
Beigene Ltd (NASDAQ:BGNE) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha